Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy

Abstract Background NR2F6 has been proposed as an alternative cancer immune checkpoint in the effector T cell compartment. However, a realistic assessment of the in vivo therapeutic potential of NR2F6 requires acute depletion. Methods Employing primary T cells isolated from Cas9-transgenic mice for...

Full description

Bibliographic Details
Main Authors: Victoria Klepsch, Maria Pommermayr, Dominik Humer, Natascha Brigo, Natascha Hermann-Kleiter, Gottfried Baier
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Cell Communication and Signaling
Subjects:
Online Access:https://doi.org/10.1186/s12964-019-0454-z